Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630344 · ClinicalTrials.gov registry record · Phase 2
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00630344 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT00630344, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance. The goal of this study is to learn if the study drug RAD001 together with Bicalutamide can slow the growth of prostate cancer. The safety of the combination will also be studied.
Interventions
- DRUG Bicalutamide
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630344
The ClinicalTrials.gov registry entry for NCT00630344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bicalutamide is the first listed.
NCT00630344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630344 about?
NCT00630344 is a clinical study titled "RAD001 and Bicalutamide for Androgen Independent Prostate Cancer". In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance. The goal of this study is to learn if the study drug RAD001 together with Bicalutamide ...
What is the current status of trial NCT00630344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00630344?
The interventions under investigation include: Bicalutamide (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00630344?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.